Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...

NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"), a leader in needle-free drug delivery, today announced the filing of a new ...

RICHMOND, Va.--(BUSINESS WIRE)--Please replace the release dated March 2, 2022, with the following corrected version due to multiple revisions. The updated release ...

The latest version of Instron’s Autoinjector Testing System was developed in close collaboration with CDMOs and pharmaceutical device manufacturers. It can perform thorough functioning testing on ...

The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying focus ...

Study met primary end point and demonstrated successful subcutaneous administration of a 10 mL biologic co-formulated with ENHANZE® in 30 seconds using Halozyme's proprietary high-volume auto-injector ...